Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen V Liu

Showing results (61-70 of 187) with videos related to

Pageof 19
Sort By:
JCO Global Oncology|March 14, 2024
Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and JapanTiciana A Leal, Anandaroop Dasgupta, Dominick Latremouille-Viau, et al.
JCO Global Oncology|September 20, 2024
Real-World Outcomes of First-Line Treatment With Anti-PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United StatesStephen V Liu, Anandaroop Dasgupta, Dominick Latremouille-Viau, et al.
JCO Precision Oncology|February 9, 2022
Entrectinib in <i>TRK</i> and <i>ROS1</i> Fusion-Positive Metastatic Pancreatic CancerMichael J Pishvaian, Ignacio Garrido-Laguna, Stephen V Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 15, 2026
Antibody-Drug Conjugates in Small-Cell Lung Cancer: DLL3, B7-H3, TROP2 and BeyondFederico Monaca, Igor Gomez-Randulfe, Javier Torres-Jiménez, et al.
Frontiers in Oncology|June 27, 2022
The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 FrameworkStephen V Liu, Misako Nagasaka, Victoria Stefaniak, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 28, 2019
Linear IgA Disease of the Gingiva Following Nivolumab TherapySushma Jonna, Mirdza Neiders, Suresh Lakshmanan, et al.
JAMA Network Open|May 25, 2022
Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung CancerSanjay Popat, Stephen V Liu, Nicolas Scheuer, et al.
Nature Communications|June 17, 2022
Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancerSanjay Popat, Stephen V Liu, Nicolas Scheuer, et al.
Annals of Translational Medicine|December 5, 2022
Classical <i>ALK</i> G1202R resistance mutation was identified in a lung adenocarcinoma patient with rare <i>LOC388942-ALK</i> fusion after sequential treatment with ALK-TKIs and anlotinib: a case reportXiaoqian Zhai, Yanyang Liu, Zuoyu Liang, et al.
Clinical Lung Cancer|June 1, 2022
Impact of Baseline Clinical Biomarkers on Treatment Outcomes in Patients With Advanced NSCLC Receiving First-line Pembrolizumab-Based TherapyIshani Joshi, Monica Peravali, Xue Geng, et al.
Pageof 19

Showing results (61-70 of 187) with videos related to

Sort By:
Pageof 19
JCO Global Oncology|March 14, 2024
Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and JapanTiciana A Leal, Anandaroop Dasgupta, Dominick Latremouille-Viau, et al.
JCO Global Oncology|September 20, 2024
Real-World Outcomes of First-Line Treatment With Anti-PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United StatesStephen V Liu, Anandaroop Dasgupta, Dominick Latremouille-Viau, et al.
JCO Precision Oncology|February 9, 2022
Entrectinib in <i>TRK</i> and <i>ROS1</i> Fusion-Positive Metastatic Pancreatic CancerMichael J Pishvaian, Ignacio Garrido-Laguna, Stephen V Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 15, 2026
Antibody-Drug Conjugates in Small-Cell Lung Cancer: DLL3, B7-H3, TROP2 and BeyondFederico Monaca, Igor Gomez-Randulfe, Javier Torres-Jiménez, et al.
Frontiers in Oncology|June 27, 2022
The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 FrameworkStephen V Liu, Misako Nagasaka, Victoria Stefaniak, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 28, 2019
Linear IgA Disease of the Gingiva Following Nivolumab TherapySushma Jonna, Mirdza Neiders, Suresh Lakshmanan, et al.
JAMA Network Open|May 25, 2022
Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung CancerSanjay Popat, Stephen V Liu, Nicolas Scheuer, et al.
Nature Communications|June 17, 2022
Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancerSanjay Popat, Stephen V Liu, Nicolas Scheuer, et al.
Annals of Translational Medicine|December 5, 2022
Classical <i>ALK</i> G1202R resistance mutation was identified in a lung adenocarcinoma patient with rare <i>LOC388942-ALK</i> fusion after sequential treatment with ALK-TKIs and anlotinib: a case reportXiaoqian Zhai, Yanyang Liu, Zuoyu Liang, et al.
Clinical Lung Cancer|June 1, 2022
Impact of Baseline Clinical Biomarkers on Treatment Outcomes in Patients With Advanced NSCLC Receiving First-line Pembrolizumab-Based TherapyIshani Joshi, Monica Peravali, Xue Geng, et al.
Pageof 19